In summary, MH is an inherited disorder characterized by a hypermetabolic state triggered by volatile inhalation anesthetics and succinylcholine. There are over 25 identified mutations of the RYR1 gene located on chromosome 19q13.1 linked to MH. However, the most reliable test for MH susceptibility is the Caffeine-Halothane Contracture Test (CHCT). This remains the gold standard. Most patients are unaware of their condition until they experience an episode under general anesthesia. Early clinical diagnosis has seen a decline in the morbidity and mortality. Improved monitoring standards and education about MH, and the availability of dantrolene has seen the mortality from acute MH fall to less than 5%. Patients identified as MH susceptible may undergo surgery with the elimination of anesthetic triggering agents. More research is needed to define MH and genetic mutations.
|Original language||English (US)|
|Number of pages||12|
|Journal||Current Reviews for Nurse Anesthetists|
|State||Published - Oct 9 2008|